Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia.

Leukemia · 2018 · PMC5843905 · PMID 28852199

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

Nevertheless, discovery proteomics is a powerful tool that guided our PRM validation study and revealed a highly significant correlation between phosphoproteins regulating RNA processing and chromatin remodeling in both JAK3 L857Q- and M511I-transformed cells.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.